InfiCure Bio is present at the 2nd NASH summit in Europe held in Frankfurt. We are presenting our new models for NASH, the NIF-HFD mouse and the MEL-HFD mouse. InfiCure did also moderate the round table discussion on preclinical models.
About wpadminThis author has not yet filled in any details.
So far wpadmin has created 21 blog entries.
InfiCure Bio is nominated in the category "Spin-off company of the year" at UmeåGalan 2018 and we are very happy and excited about it. UmeåGalan will be held on November 8th and this is an event aimed at celebrating companies and entrepreneurs working for development and growth of the region. The nominated companies were revealed [...]
We are happy to announce that a new publication on the N-IF mouse is published in Plos One. The publication shows treatment of liver fibrosis in the N-IF mouse and the results verify that the fibrosis, which spontaneously develops in the N-IF mouse, is treatable.
We are proud to announce that InfiCure Bio has signed a collaboration agreement with the global biotech company CSL (https://www.csl.com). The signing of the contract entails collaboration between InfiCure Bio and CSL in testing their experimental anti-fibrotic reagent in the N-IF mouse, InfiCure’s unique, proprietary model for fibrosis. The management team of InfiCure [...]
InfiCure Bio is one of the companies on the map of Swedish precision medicine industry companies 2018. In the report “Precision Medicine The Swedish Industry Guide 2018”, SwedenBIO has made a map of Swedish companies in precision medicine. On page 12 you can find InfiCure Bio. We are happy to see that Umeå is on [...]
Maria Hörnberg is now the new Product Manager at InfiCure Bio. Maria has a PhD in Molecular Biology and prior to her position at InfiCure Bio she was the coordinator of the Transgene Core Facility at Umeå University. We are very happy to have her on board!
InfiCure Bio was awarded Innovative Start up Phase II from Vinnova. This opens up an additional market segment for InfiCure Bio, since the grant will fund the validation of additional models for NASH.
InfiCure Bio is one of the sponsors of Anti-Fibrotic Drug Development Summit (AFDD) at Hyatt Regency in Boston. The AFDD brings together important experts in different areas of drug development with the aim to find better solutions and faster development of drugs to treat fibrosis.
Our application to Horizon 2020 SME Phase I was granted! Read about our project in the Horizon 2020 SME Instrument data hub.
PartnerInvest Norr and Nordic Light Capital are local investors investing in InfiCure Bio. This is a great opportunity for InfiCure which makes it possible for the company to go global and expand its business. Read more about inte investment: https://affarsliv24.vk.se/2107674/riskkapital-till-umeaforetag-stor-global-potential